An impressive crowd gathered yesterday (Nov. 21) at Chiesi Pharmaceutical Group to mark the much-anticipated start of work on the Biotech Center of Excellence, bringing the future of medicine to Parma.
Guests, including Deputy Minister of Affairs and Made in Italy, Valentino Valentini, were on hand to celebrate the start of work on the building, the new Italian and international center of excellence for the production of biological medicines.
The center is expected to open in 2024 and be fully operational. It will specialize in the development and production of the active ingredients of monoclonal antibodies (produced by recombinant DNA techniques from a single type of immune cell), enzymes and others protein.
Chiesi focuses on biological medicines
“The success of Made in Italy is possible thanks to realities such as Chiesi, ranked first among private companies for investment in research and development in Italy: more than 20% of turnover, about half a billion euros in 2022, and first place for the number of patents.
“The Chiesi Group is now focusing on biologics, including monoclonal antibodies, with an investment of EUR 85 million in an international center of excellence in Parma, confirming the corporate culture focused on patients, innovation and maximum environmental sustainability,” said Valentini.
Chiesi wants to further develop the specialized expertise that is already present Italy and aims to attract new talent and technical skills to work from cells to the finished drug and packaging for the global market.
Chiesi is keen to develop expertise
The establishment of the Biotech Center of Excellence is, according to Chiesi, the answer needed to the challenges posed by the pandemicdemonstrating the need to improve the resilience of the healthcare system, including sustainability improvements.
Today, only 22% of all new treatments being developed worldwide come from European countries, partly due to slower growth in research and development and investment across the region.
Alberto Chiesi, president of the family business Chiesi group, said: “Today we are proud to present this new center of expertise in the presence of local, regional and national institutions. It has always been essential for Chiesi to invest in research with the aim of making our country, and Europe, a leader in production and access to innovation. In addition, the new Biotech Center represents a strong message of growth for Italy and in particular for the Parma community, where Chiesi was founded and where its headquarters are still located.
Emilia-Romagna to compete at the international level
The event, held at the Chiesi San Leonardo production site in Parma, where the new center is being built, was attended by both Valentino Valentini and the President of the Emilia-Romagna Region, Stefano Bonaccini, Councilor Vincenzo Colla, Mayor of Parma Michele Guerra, the president of Farm Industria Marcello Cattani, and the top management of the group.
“Research, innovation and new technologies are the strategic drivers that will enable an area like Emilia-Romagna to compete on an international level now and in the near future. For this reason, the opening of this center is excellent news that will enrich our region with a new place of excellence in pharmaceuticals. As an institution, we intend to stand for the entrepreneurial reality that invests in good jobs, innovation and research, giving them more and more opportunities.
“Starting with a regional system enriched, with the inauguration on Thursday at the Technopole of Bologna, of the European supercomputer Leonardo, the fourth largest in the world in terms of computing power, an extraordinary infrastructure, at the service of Italy and Europe, which also includes pharmaceuticals and biotechnology as several sectors with the greatest potential,” said Stefano Bonaccini, President of the Emilia-Romagna Region.
Chiesi’s commitment to research in Italy
The company says that if Italy and Europe are to become leaders in raw materials and access to innovation, it is fundamental that European and national institutions work to create standards and regulations that are future-proof. In addition, it said, it is also critical to start maintaining a system of strong incentives that encourages scientific progress, technology and innovative medicines. In order to focus on the added value for patients and the healthcare system, it is necessary to strive for regulatory ecosystems that look beyond the concepts of technology-based innovation evaluation.
Antonio Magnelli, head of the global manufacturing division of the Chiesi Group, said: “With the Biotech Center, the company aims to internalize its expertise in order to have an effective research facility that can develop new drugs and facilitate integration with the manufacturing plant in our factory. region. Our goal will not be to compete with the big multinationals, but to become a center of excellence in our molecules. The Biotech Center will not only be at the forefront of biotechnology; it will also be developed with the same prerogatives as the company’s other facilities. By investing in biotech, we invest in the medicine of the future and prepare for the future demand for healthcare.”
The meeting was also an opportunity to celebrate Chiesi’s commitment to research in Italy; indeed, the Group continues to invest in the region by implementing projects that generate value and new highly skilled jobs. The new therapeutic opportunities offered by the Biotech Center of Excellence will enable the company to become a major player in the biopharmaceutical sector, an industry that has been growing steadily for about 10 years.